Vitamin D Deficiency and Risk of Cardiovascular Disease

Wang, Thomas J.; Pencina, Michael J.; Booth, Sarah L.; Jacques, Paul F.; Ingelsson, Erik; Lanier, Katherine J.; Benjamin, Emelia J.; D’Agostino, Ralph B.; Wolf, Myles; Vasan, Ramachandran S.

doi:10.1161/circulationaha.107.706127

Cited by 2,147 publications

(1,690 citation statements)

References 63 publications

Supporting

Mentioning

1,558

Contrasting

Unclassified

Order By: Relevance

“…This is in line with prospective population-based studies which showed that low 25(OH)D levels are an independent risk factor for cardiovascular events and cardiovascular mortality [101][102][103]. We are aware that discussing the causality of vitamin D deficiency for chronic diseases is a difficult task because sun exposure is the main determinant of vitamin D status and is usually inversely correlated with the severity of illness.…”

Section: Clinical Consequences and Summarysupporting

confidence: 77%

Vitamin D deficiency and myocardial diseases

Pilz

Tomaschitz

Drechsler

et al. 2010

Molecular Nutrition Food Res

135

142

View full text Add to dashboard Cite

Vitamin D deficiency is common among patients with myocardial diseases because sun-induced vitamin D production in the skin and dietary intake of vitamin D is often insufficient. Knockout mice for the vitamin D receptor develop myocardial hypertrophy and dysfunction. It has also been shown that children with rickets who suffered from severe heart failure could be successfully treated with supplementation of vitamin D plus calcium. In adults, almost all patients with heart failure exhibit reduced 25-hydroxyvitamin D levels, which are used to classify the vitamin D status. In prospective studies, vitamin D deficiency was an independent risk factor for mortality, deaths due to heart failure and sudden cardiac death. Several vitamin D effects on the electrophysiology, contractility, and structure of the heart suggest that vitamin D deficiency might be a causal factor for myocardial diseases. Data from interventional trials, however, are rare and urgently needed to elucidate whether vitamin D supplementation is useful for the treatment of myocardial diseases. In our opinion, the current knowledge of the beneficial effects of vitamin D on myocardial and overall health strongly argue for vitamin D supplementation in all vitamin D-deficient patients with or at high risk for myocardial diseases.

show abstract

Section: Clinical Consequences and Summarysupporting

confidence: 77%

Vitamin D deficiency and myocardial diseases

Pilz

Tomaschitz

Drechsler

et al. 2010

Molecular Nutrition Food Res

135

142

View full text Add to dashboard Cite

show abstract

“…Many reports Karasik et al 2002) have documented a decrement in IGF1 plasma levels with age in humans. (Wang et al 2008), and cancers of the breast, colon, and prostate (Martinez et al 1996;Garland et al 1989;John et al 1999). A recent meta-analysis of randomized controlled trials suggested that vitamin D supplementation led to significant reductions in mortality (Autier and Gandini 2007).…”

Section: Biochemical and Endocrine Serum Markersmentioning

confidence: 99%

How pleiotropic genetics of the musculoskeletal system can inform genomics and phenomics of aging

Karasik

2010

AGE

View full text Add to dashboard Cite

Genetic study can provide insight into the biologic mechanisms underlying inter-individual differences in susceptibility to (or resistance to) organisms' aging. Recent advances in molecular genetics and genetic epidemiology provide the necessary tools to perform a study of the genetic sources of biological aging. However, to be successful, the genetic study of a complex condition requires a heritable phenotype to be developed and validated. Genome-wide association studies offer an unbiased approach to identify new candidate genes for human diseases. It is hypothesized that convergent results from multiple aging-related traits will point out the genes responsible for the general aging of the organism. This perspective focuses on the musculoskeletal aging as an example of an approach to identify a downstream common pathway that summarizes aging processes. Since the musculoskeletal traits are linked to the state of many vital functions, disability, and ultimately survival rates, we postulate that there is significance in studying musculoskeletal aging. Construction of an integrated phenotype of aging can be achieved based on shared genetics among multiple musculoskeletal biomarkers. Valid biomarkers from other systems of the organism should be similarly explored. The new composite aging score needs to be validated by determining whether it predicts all-cause mortality, incidences of major chronic diseases, and disability late in life. Comprehensive databases on biomarkers of musculoskeletal aging in multiple large cohort studies, along with information on various health outcomes, are needed to validate the proposed measure of biological aging.

show abstract

“…Low vitamin D levels are associated with a higher risk of developing type 2 diabetes [4], worse glycaemic control in type 2 diabetes, higher serum lipid levels and a higher prevalence of cardiovascular disease [3]. Low vitamin D levels are also associated with an increased risk of hypertension and cardiovascular events in population-based studies [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

The effect of different doses of vitamin D3 on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial

et al. 2010

View full text Add to dashboard Cite

Aims/hypothesis Low 25-hydroxyvitamin D levels predict future cardiovascular events and are common in patients with type 2 diabetes. We compared the effect of 100,000 and 200,000 IU doses of vitamin D 3 on endothelial function, blood pressure and markers of glycaemic control in patients with type 2 diabetes. Methods This was a randomised, parallel group, placebocontrolled trial. Patients with type 2 diabetes and baseline 25-hydroxyvitamin D levels <100 nmol/l were enrolled from community and hospital-based diabetes clinics. Participants were assessed in a university department of clinical pharmacology and received a single oral dose of placebo or vitamin D 3 (100,000 IU or 200,000 IU) at baseline, randomly allocated via numbered bottles prepared offsite; participants and investigators were both blinded to treatment allocation. Endothelial function, office blood pressure, B-type natriuretic peptide, insulin resistance and glycosylated haemoglobin were measured at baseline, and at 8 and 16 weeks.

show abstract

Vitamin D Deficiency and Risk of Cardiovascular Disease

Abstract: Background-Vitamin

Cited by 2,147 publications

References 63 publications

Vitamin D deficiency and myocardial diseases

Vitamin D deficiency and myocardial diseases

How pleiotropic genetics of the musculoskeletal system can inform genomics and phenomics of aging

The effect of different doses of vitamin D3 on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial

Contact Info

Product

Resources

About